Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme (NASDAQ: HALO) announced a global collaboration and license agreement with GSK to apply Halozyme's ENHANZE® technology to develop subcutaneous formulations for multiple oncology targets, including antibody drug conjugates (ADCs).
GSK will pay an upfront fee, may pay future milestones, and Halozyme will receive royalties on net sales. The first clinical trial is projected to start in 2026, and the deal includes an option for additional targets.
Halozyme (Nasdaq: HALO) and Oruka (Nasdaq: ORKA) entered a global exclusive collaboration and license agreement dated May 6, 2026, granting Oruka rights to Halozyme's Hypercon™ microparticle technology for ORKA-001 (psoriasis) and an option for one additional target.
Terms include an upfront payment, potential future milestone payments, and mid-single digit royalties to Halozyme on net sales of Hypercon-enabled products.
Halozyme (Nasdaq: HALO) will report first quarter 2026 financial and operating results on Monday, May 11, 2026 after market close. A conference call is scheduled for May 11, 2026 at 1:30pm PT / 4:30pm ET.
According to Halozyme, the call requires pre-registration and will be available via live webcast and replay in the company's Investors section at www.halozyme.com.
Halozyme (Nasdaq: HALO) appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove brings more than 30 years of financial leadership, including roles leading investor relations at Johnson & Johnson and serving as CFO for J&J's Pharmaceuticals business, a unit generating over $50 billion in annual revenue.
Halozyme (Nasdaq: HALO) announced a global exclusive collaboration and license with Vertex Pharmaceuticals on April 7, 2026 to apply Halozyme's Hypercon™ microparticle technology to up to three drug targets. Vertex will pay a $15 million upfront, potential future milestones, and royalties on net sales.
The agreement aims to reduce injection volume and enable at-home dosing for biologics through Hypercon's hyperconcentration capability.
Halozyme (NASDAQ: HALO) named David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay will oversee all financial operations while the company continues its search for a permanent CFO.
He brings more than 30 years of biotech financial leadership and previously served as Halozyme CFO from 2003–2009 and 2013–2015. Halozyme has engaged a leading executive search firm to identify a permanent CFO; Ramsay will remain until an appointment is made.
Halozyme (NASDAQ: HALO) announced that Johnson & Johnson received U.S. FDA approval (March 6, 2026) for TECVAYLI (teclistamab) combined with DARZALEX FASPRO for adults with relapsed/refractory multiple myeloma after ≥1 prior therapy. The approval followed Phase 3 MajesTEC-3 data showing statistically significant PFS and OS benefits.
Key trial results: hazard ratio 0.17 for progression or death (95% CI 0.12–0.23; P<0.0001) and a three-year PFS rate of 83% after median three-year follow-up.
Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, President and CEO, will present and hold investor meetings at three upcoming conferences: TD Cowen on March 3, 2026, Leerink on March 10, 2026, and The Citizens Life Sciences Conference on March 11, 2026.
Live audio webcasts will be available on the company investor relations website, with replays accessible for 90 days after each event.
Halozyme (NASDAQ: HALO) reported record full‑year 2025 total revenue of $1.397 billion, driven by $867.8 million in royalties (+52% YoY). The company completed acquisitions of Elektrofi (Hypercon) and Surf Bio, issued convertible notes, and reiterated 2026 guidance: $1.71–$1.81B revenue, $1.125–$1.205B adjusted EBITDA, and $7.75–$8.25 non‑GAAP EPS.
Net income was $316.9M (includes $284.9M acquired IPR&D); cash and equivalents declined to $145.4M.
Halozyme (NASDAQ: HALO) will report its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, released after the close of trading.
According to the company, a conference call to discuss results will be held on February 17, 2026 at 1:30pm PT / 4:30pm ET, with live webcast and replay available via Halozyme's Investors website.